NCT04581356View on ClinicalTrials.gov

Voxelotor Sickle Cell Exercise Study

PHASE4CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

October 25, 2021

Study Completion Date

December 29, 2021

Conditions
Sickle Cell Anemia
Interventions
DRUG

Voxelotor

daily voxelotor 1500mg oral medication

Trial Locations (1)

22031

Pediatric Specialist of Virginia, Fairfax

Sponsors
All Listed Sponsors
collaborator

Pediatrix

OTHER

collaborator

University of California, San Francisco

OTHER

collaborator

Global Blood Therapeutics

INDUSTRY

lead

Elizabeth Yang, MD, PhD

OTHER

NCT04581356 - Voxelotor Sickle Cell Exercise Study | Biotech Hunter | Biotech Hunter